Trial Outcomes & Findings for Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance (NCT NCT00926536)
NCT ID: NCT00926536
Last Updated: 2016-04-04
Results Overview
Dose area product (DAP) is a measure of the entire amount of energy (radiation dose) delivered to the patient by the beam (indicator of stochastic dose)
COMPLETED
NA
84 participants
Duration of a TACE procedure, an average of 2 hours
2016-04-04
Participant Flow
Study was open from 01/13/2009 thru 10/13/2010. During this period, subjects with HCC who were scheduled to undergo TACE were approached for permission to participate in the study.
Participant milestones
| Measure |
C-arm CT +DSA as Needed
C-arm CT in imaging guidance of TACE supplemented with DSA as needed for vessel tracking and navigation
|
DSA Only
Only Digital subtraction images used for vessel tracking and tumor navigation
|
|---|---|---|
|
Overall Study
STARTED
|
44
|
43
|
|
Overall Study
COMPLETED
|
43
|
41
|
|
Overall Study
NOT COMPLETED
|
1
|
2
|
Reasons for withdrawal
| Measure |
C-arm CT +DSA as Needed
C-arm CT in imaging guidance of TACE supplemented with DSA as needed for vessel tracking and navigation
|
DSA Only
Only Digital subtraction images used for vessel tracking and tumor navigation
|
|---|---|---|
|
Overall Study
Physician Decision
|
1
|
2
|
Baseline Characteristics
Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance
Baseline characteristics by cohort
| Measure |
C-arm CT + DSA as Needed
n=43 Participants
C-arm CT in imaging guidance of TACE supplemented by DSA as needed for vessel navigation and tracking
|
DSA Only
n=41 Participants
DSA images only used for vessel navigation and tracking
|
Total
n=84 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Customized
<=18 years
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
0 participants
n=5 Participants
|
|
Age, Customized
Over 18 years old
|
43 participants
n=5 Participants
|
41 participants
n=7 Participants
|
84 participants
n=5 Participants
|
|
Sex: Female, Male
Female
|
6 Participants
n=5 Participants
|
12 Participants
n=7 Participants
|
18 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
37 Participants
n=5 Participants
|
29 Participants
n=7 Participants
|
66 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Duration of a TACE procedure, an average of 2 hoursPopulation: DAP measured in both groups
Dose area product (DAP) is a measure of the entire amount of energy (radiation dose) delivered to the patient by the beam (indicator of stochastic dose)
Outcome measures
| Measure |
C-arm CT +DSA as Needed
n=43 Participants
C-arm CT images used for navigational purposes supplemented by DSA if needed
|
DSA Only
n=41 Participants
Only DSA imaging used for navigational purposes
|
|---|---|---|
|
Dose Area Product (DAP)
|
184.2 Gy.cm2
Interval 148.2 to 220.2
|
137.4 Gy.cm2
Interval 101.1 to 173.7
|
PRIMARY outcome
Timeframe: Duration of a TACE procedure, an average of 2 hoursPopulation: CD measured in both groups
CD - a measurement of total radiation to the skin (measure of a deterministic dose)
Outcome measures
| Measure |
C-arm CT +DSA as Needed
n=43 Participants
C-arm CT images used for navigational purposes supplemented by DSA if needed
|
DSA Only
n=41 Participants
Only DSA imaging used for navigational purposes
|
|---|---|---|
|
Cumulative Dose (CD), a Measure of Radiation Dose
|
626.4 mGy
Interval 439.5 to 813.3
|
784.7 mGy
Interval 537.3 to 1032.1
|
Adverse Events
C-arm CT + DSA as Needed
DSA Only
Serious adverse events
| Measure |
C-arm CT + DSA as Needed
n=43 participants at risk
C-arm CT used for the purposes of navigation, supplemented by DSA if needed
|
DSA Only
n=41 participants at risk
DSA only used for navigation
|
|---|---|---|
|
Surgical and medical procedures
Arterial Hematoma
|
0.00%
0/43 • The duration of the procedure, since this was an imaging study. TACE procedures are an average of 2 hours.
|
2.4%
1/41 • Number of events 1 • The duration of the procedure, since this was an imaging study. TACE procedures are an average of 2 hours.
|
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: LTE60